Skip to main content


Malaria is a parasite that is passed to people by the bite of an infected mosquito. The most serious type of malaria is called Plasmodium falciparum. When people get sick with malaria, they may experience symptoms of high fever and flu-like symptoms. If untreated, malaria can cause serious illness or death.

You are being asked to participate in this study because you are a healthy adult (18-50 years) who has not had malaria or received an experimental malaria vaccine, in the past, and degree to donate blood for a research study and agree not to travel to a malaria region during the study.

The Center for Vaccine Development and Global Health (CVD), an organized research center of the University of Maryland School of Medicine, is conducting an experimental human monoclonal antibody study and challenge in collaboration with the National Institutes of Health. Monoclonal means that all the antibodies in the product are the same. As part of this portion of the trial, you will be in the control arm and will not receive the monoclonal antibody. The challenge means that you will be exposed to the malaria parasite by the bite of a mosquito. There are no direct benefits to participation, but the results may help prevent malaria.

This study will recruit healthy adults ages 18-50 years. This study will require approximately 22 clinic visits including daily visits from Days 7-18 following exposure to a malaria challenge. Eligible participants will be compensated up to $1,630 for completing all the study visits and procedures.

Ready to get started?

To volunteer: